RAPT Therapeutics, Inc. (RAPT) — Financial statements
Income statement, balance sheet, and cash flow for RAPT Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 2↓60.0% | 4↓24.4% | 5 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00↓100.0% | 2↓60.0% | 4↓24.4% | 5 | |
| Operating Expenses | ||||||
| R&D Expenses | 107↑6.2% | 101↑50.6% | 67↑17.7% | 57↑25.3% | 45 | |
| General & Administrative Expenses | 29↑10.8% | 26↑28.8% | 20↑26.2% | 16↑25.6% | 13 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 29↑10.8% | 26↑28.8% | 20↑26.2% | 16↑25.6% | 13 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 136↑7.1% | 127↑45.5% | 87↑19.6% | 73↑25.3% | 58 | |
| Total Costs & Expenses | 136↑7.1% | 127↑45.5% | 87↑19.6% | 73↑25.3% | 58 | |
| Operating Results | ||||||
| Operating Income | -136↓7.1% | -127↓48.1% | -86↓24.0% | -69↓30.1% | -53 | |
| Depreciation & Amortization | 1↓1.1% | 1↑16.1% | 1↑5.1% | 1.00↓11.3% | 1 | |
| EBITDA | -135↓7.2% | -126↓48.5% | -85↓24.2% | -68↓30.9% | -52 | |
| EBIT | -136↓7.1% | -127↓48.1% | -86↓24.0% | -69↓30.1% | -53 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 6↓39.2% | 10↑424.5% | 2↑39040.0% | 0.01↓99.6% | 1 | |
| Income Before Tax | -130↓11.2% | -117↓39.3% | -84↓21.1% | -69↓33.3% | -52 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.99 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -130↓11.2% | -117↓39.3% | -84↓21.1% | -69↓30.8% | -53 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -130↓11.2% | -117↓39.3% | -84↓21.1% | -69↓30.8% | -53 | |
| Bottom-Line Net Income | -130↓11.2% | -117↓39.3% | -84↓21.1% | -69↓30.8% | -53 | |
| EPS (Basic) | -25.49↓4.6% | -24.37↓18.2% | -20.61↓2.0% | -20.21↓15.3% | -17.53 | |
| EPS (Diluted) | -25.49↓4.6% | -24.37↓18.2% | -20.61↓2.0% | -20.21↓15.3% | -17.53 | |
| Weighted Average Shares | 5↑6.3% | 5↑17.8% | 4↑18.8% | 3↑13.5% | 3 | |
| Weighted Average Diluted Shares | 5↑6.3% | 5↑17.8% | 4↑18.8% | 3↑13.5% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.